2 ϫ 10 into a vaginal suppository, and patients were randomized as described elsewhere [8] . There were 3 randomized treatment groups: Group 1 received vaccine suppositories at weeks 0, 1, 2, 6, 10, and 14; group 2 also received vaccine suppositories at weeks 0, 1, and 2 but at weeks 6, 10, and 14, they received placebo suppositories; and group 3 received six placebo suppositories at the same time points. All patients were followed through 24 weeks.
Thirty-six women have completed the phase II extended trial. Patients were 18-74 years old, and all had had three or more UTIs during the previous year. All of the women were asked if they were taking oral or vaginal estrogen and whether they were sexually active. All women had a urologic evaluation consisting of an excretory urogram or renal ultrasound and cystoscopy. Reasons for exclusion and pregnancy considerations were as previously used [8] . Antibiotic prophylaxis was discontinued for all women at the outset; during the 24-week trial, infections were treated with 3 days of appropriate antibiotics. Speculum examinations and vaginal cultures were done at the outset and repeated when abnormal vaginal secretions or symptoms developed. When Gram's staining of vaginal swab samples showed large numbers of large gram-positive rods, lactobacillus vaginal colonization was considered to be present. Further characterization of vaginal flora was not done. Vaginal irrigants (obtained with 5 mL of sterile saline) were used for vaginal antibody determinations. For vaginal suppository instillation, the suppository was inserted into the cephalad vagina of supine patients, and patients remained supine for 15 min. Urine, serum, and vaginal irrigant samples were obtained at each visit, and antibodies were quantified by an ELISA technique [11] .
Patient characteristics were compared statistically using Fisher's two-tailed exact test and the Kruskal-Wallis one-way analysis of variance [12] . Intervals until initial reinfections, average number of infections, and proportion remaining infection free at 24 weeks were compared using the log-rank test. Changes in antibody levels were compared by repeated-measures analysis of variance for unbalanced data.
Results
The women in the 3 treatment groups (vaccine-vaccine, vaccine-placebo, and placebo-placebo) did not differ in mean age, estrogen usage, sexual activity, or vaginal lactobacillus colonization (table 1) . No patient discontinued treatment for adverse reactions or reported heavy vaginal discharge or interference with sexual intercourse. Although we did not always have pre-study urine culture results for women entering the study, there was no apparent shift in the organisms causing infections during the study.
The reinfection intervals for women in group 1 (vaccinevaccine) but not group 2 (vaccine-placebo) were significantly delayed in the interval until first reinfection compared with those for group 3 (placebo-placebo; ) (figure 1). There P p .045 were no reinfections in 50% of group 1, 25% of group 2, and 17% of group 3 by the end of the study. These proportions were not significantly different overall (
). In patients P p .08 with reinfections, the median times to reinfection were 46, 21, and 16 days in groups 1, 2, and 3, respectively. While the women receiving vaccine plus boosters had the longest median time until reinfection, the intervals were not statistically different between groups ( ). The average number of infections P p .06 per patient over the 6 months was 1.2, 1.8, and 1.5 in groups 1, 2, and 3, respectively. There was no overall treatment effect seen for this parameter ( ). P p .59 While some individuals showed strain-specific increases in antibodies, we could not detect differences in mean total or E. coli-specific immunoglobulin levels in urine or vaginal irrigants among the 3 groups over the course of the study (table 2) . Similarly, there were no significant differences in mean serum antibody levels over time in the 3 groups.
Discussion
The hypothesis on which UTI vaccine development is based is that urinary antibody can be increased and can prevent bacterial adherence to urinary epithelium in vivo, as shown in vitro by Svanborg et al. [13] . In addition, antibodies directed against other bacterial virulence factors can inhibit their biologic activity and decrease infectivity or persistence. The whole-cell vaccine utilized in this study is effective when administered intramuscularly, but it has endotoxin side effects [10] . Since UTIs are caused by a wide spectrum of urinary tract pathogens, the 10 organisms that constitute the vaccine conceptually offer the advantage of a multivalent vaccine [14, 15] . Strategies to develop a mucosal vaccine for UTIs seek to provide antibacterial antibodies on mucosal surfaces of the lower genito-urinary tract in a safe and effective way. Several studies in non-UTI systems have suggested vaginal immunization as a route to stimulate local cervicovaginal antibodies [3] [4] [5] .
Our efforts to stimulate mucosal immunity through vaginal immunization started with animal models and have now progressed through three human clinical trials. Following vaginal immunization, rats showed decreased bacterial adherence to bladder epithelium, less mucosal disruption after induced infection, and a shorter UTI resolution time [16] . Monkeys vaginally immunized with this vaccine evidenced reduced infection levels but did not show increased serum or urine antibody levels [6] . In our human phase I clinical trial, no adverse reactions were noted after vaginal instillation with the vaccine, but vaginal and urinary IgG and IgA increased [7] . In our first randomized, blind, placebo-controlled phase II clinical trial, we noted that for up to 8 weeks after beginning treatment, women receiving vaccine had a significant delay in acquiring their first reinfection as compared with women who were given placebo [8] .
In the current trial, our goal was to extend the protection period by use of booster suppositories. Again there were no adverse reactions. Women who received the initial vaccine doses plus three booster doses had a significant delay in the time until the first reinfection over their entire study period as compared with placebo-treated women. Wide variations in serum, urine, and anti-E. coli vaginal antibodies were found, and no significant mean differences were noted between groups. Explanations for this include variations in individual immune responses, varying states of patient hydration, and an inability to rigorously NOTE. Group 1 received vaginal suppository immunogen at weeks 0, 1, 2, 6, 10, and 14; group 2 received vaginal suppository immunogen at weeks 0, 1, and 2 and placebo suppositories at weeks 6, 10, and 14; group 3 received placebo vaginal suppositories at weeks 0, 1, 2, 6, 10, and 14.
control collection methods for cervicovaginal secretions. Vaginal immunization for recurrent UTIs is a safe and effective treatment method. Our current research goals are to increase the immunogenicity of the vaginal suppository, further extend the period of protection, and include other centers in future clinical trials.
